Showing 5531-5540 of 8820 results for "".
- ISHRS: Hair Restoration Surgery at All-Time Highhttps://practicaldermatology.com/news/ishrs-hair-restoration-surgery-at-all-time-high/2458029/Hair restoration is having a moment. The worldwide volume of surgical hair restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures performed worldwide in 2016, according to the latest’s statistics from the
- Alastin Skincare Launches Trihex Transition Duo at ASDShttps://practicaldermatology.com/news/alastin-skincare-launches-trihex-transition-duo-at-asds/2458027/ALASTIN Skincare®, Inc. is launching the TriHex Transition Duo at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. The TriHex Transition Duo includes a full-size Regenerating Skin Nectar for use pre- and post-procedure and a
- FDA Adds Third Approved Indication for Botox Cosmetic: Forehead Lineshttps://practicaldermatology.com/news/fda-adds-third-approved-indication-for-botox-cosmetic-forehead-lines/2458032/Allergan plc's Botox Cosmetic received ts third FDA indication—the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults. This approval makes the brand the first and only neurotoxin indicated for three facial tre
- Dermavant Sciences Appoints Vince Ippolito as President and COOhttps://practicaldermatology.com/news/dermavant-sciences-appoints-vince-ippolito-as-president-and-coo/2458034/Dermavant Sciences, a biopharmaceutical company focused on developing therapies for dermatologic conditions, appointed Vince Ippolito as President and Chief Operating Officer. "I am extremely pleased to welcome Vince Ippolito
- Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AKhttps://practicaldermatology.com/news/update-from-dfb-soria-on-enrollment-in-phase-2-clinical-trial-of-nanoparticle-paclitaxel-ointment-for-ak/2458039/DFB Soria, a clinical-stage pharmaceutical development company, and an affiliate of NanOlogy™, completed the second of four patient cohorts enrolled in a Phase 2 actinic keratosis (AK) clinical trial of a topical ointment containing nanoparticle
- Sciton and the Young Survival Coalition Partner for Breast Cancer Awarenesshttps://practicaldermatology.com/news/sciton-and-the-young-survival-coalition-partner-for-breast-cancer-awareness/2458041/Sciton, Inc.’s Women's Health Group division and the Young Survival Coalition (YSC) are partnering to raise awareness about women's vaginal health, in particular, those who are recovering from breast can
- Dr. Michael H. Gold Joins AIVITA Scientific Advisory Boardhttps://practicaldermatology.com/news/dr-michael-h-gold-joins-aivita-scientific-advisory-board/2458042/Nashville dermatologist Michael H. Gold, MD, has joined AIVITA Biomedical’s Scientific Advisory Board. His addition comes as AIVITA prepares to launch its upcoming ROOT OF SKINTM line of rejuvenating skincare products. Dr. Gold,
- New Data: Aclaris' A-101 40% Safely Banishes Facial SK Lesionshttps://practicaldermatology.com/news/new-data-aclaris-a-101-40-safely-banishes-facial-sk-lesions/2458044/Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such as the face, with minimal risk of s
- Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/two-year-data-tremfya-guselkumab-achieves-consistent-rates-of-skin-clearance-in-moderate-to-severe-plaque-psoriasis/2458046/New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate to severe plaque psoriasis receiving the subcutaneously administered anti-interleukin (IL)-23 mo
- EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe ADhttps://practicaldermatology.com/news/eadv-news-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-ad/2458050/Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately controlled or intolerant to cyclosporine A (C